Details of Disease

General Information of Disease (ID: DIS27206)

Disease Name	Irritable bowel syndrome
Synonyms	psychogenic IBS; irritable bowel syndrome; irritable colon; IBS; mucus colitis; spastic colon; IBD
Disease Class	DD91: Irritable bowel syndrome
Definition	Irritable bowel syndrome (IBS) is a chronic functional condition of the lower gastrointestinal (GI) tract characterized by abdominal pain or discomfort and disordered bowel habit (diarrhea, constipation, or fluctuation between the two).
Disease Hierarchy	DIS6SVEE: Syndromic disease DISGPMUQ: Intestinal disorder DIS27206: Irritable bowel syndrome
ICD Code	ICD-11 ICD-11: DD91.0 ICD-10 ICD-10: K55-K64, K58 ICD-9 ICD-9: 564.1, 787.91 Expand ICD-11 'DD91.0 Expand ICD-10 'K55-K64; 'K58 Expand ICD-9 564.1,787.91
Disease Identifiers	MONDO ID MONDO_0005052 MESH ID D043183 UMLS CUI C0022104 MedGen ID 5897 SNOMED CT ID 10743008

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 23 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Alosetron	DML2A03	Approved	Small molecular drug	[1]
AST-120	DM718MD	Approved	Small molecular drug	[2]
Calcium polycarbophil	DMU381I	Approved	NA	[2]
Chlordiazepoxide	DMTN5XI	Approved	Small molecular drug	[3]
Clidinium	DMUMQZ0	Approved	Small molecular drug	[4]
Dicyclomine	DMZSDGX	Approved	Small molecular drug	[5]
Drotaverine	DM96FA1	Approved	Small molecular drug	[2]
Homatropine Methylbromide	DMGBPSH	Approved	Small molecular drug	[6]
Ispaghula	DMWCRN1	Approved	NA	[7]
Linaclotide	DM4EGV0	Approved	Small molecular drug	[8]
MD-1100	DM4IAKR	Approved	Small molecular drug	[7]
Mebeverine	DMNOBFQ	Approved	Small molecular drug	[7]
Methantheline	DM8X4A1	Approved	Small molecular drug	[2]
Milnacipran	DMBFE74	Approved	Small molecular drug	[9]
Plecanatide	DMKEX7O	Approved	Small molecular drug	[10]
Prifinium	DMMZB0K	Approved	Small molecular drug	[2]
R0-93877	DMM4U9G	Approved	Small molecular drug	[11]
Ramosetron	DMH7GN8	Approved	Small molecular drug	[12]
Scopolamine	DMOM8AL	Approved	Small molecular drug	[13]
Sulfasalazine	DMICA9H	Approved	Small molecular drug	[2]
Tegaserod	DM3XYD1	Approved	Small molecular drug	[2]
Tenapanor	DMCOZJY	Approved	Small molecular drug	[14]
Trimebutine	DMPYQ7B	Approved	Small molecular drug	[2]
------------------------------------------------------------------------------------


⏷ Show the Full List of 23 Drug(s)

This Disease is Treated as An Indication in 23 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Cilansetron	DMP0NGX	Phase 3	Small molecular drug	[15]
Ibodutant	DMT67EH	Phase 3	Small molecular drug	[16]
M-17 E. Coli	DMJ0864	Phase 3	NA	[17]
Pinaverium bromide	DM7OSHC	Phase 3	Small molecular drug	[7]
Renzapride	DM7HQNX	Phase 3	Small molecular drug	[18]
Arverapamil	DML27AE	Phase 2	Small molecular drug	[7]
ASP-7147	DMGDF2X	Phase 2	NA	[19]
Blautix	DMCP3YO	Phase 2	Live biotherapeutic	[20]
DDP-225	DM9REBL	Phase 2	Small molecular drug	[7]
Dextofisopam	DM9L15R	Phase 2	Small molecular drug	[7]
GTP-010	DMN6IDO	Phase 2	NA	[7]
LX-1031	DMZ2XAP	Phase 2	Small molecular drug	[21]
LX-1033	DM5PK9S	Phase 2	NA	[22]
ONO-2952	DMOGYQ0	Phase 2	NA	[23]
ORP-101	DMSH20P	Phase 2	Small molecule	[24]
Pumosetrag	DMBUSNL	Phase 2	Small molecular drug	[7]
SB-207266A	DM27KFY	Phase 2	Small molecular drug	[25]
Talnetant	DMQKZDT	Phase 2	Small molecular drug	[26]
TC-6499-12	DMWPI2U	Phase 2	NA	[27]
Tofisopam	DMTGNWU	Phase 2	Small molecular drug	[28]
CIN-103	DMTB925	Phase 1	Small molecule	[29]
DA-6886	DMKPAOD	Phase 1	NA	[30]
RWJ-68023	DM4O07Q	Phase 1	NA	[31]
------------------------------------------------------------------------------------


⏷ Show the Full List of 23 Drug(s)

This Disease is Treated as An Indication in 6 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
DNK-333	DM4ZO01	Discontinued in Phase 2	Small molecular drug	[32]
Ezlopitant	DMTUPZ2	Discontinued in Phase 2	Small molecular drug	[33]
Fabesetron	DMMSFK0	Discontinued in Phase 2	Small molecular drug	[34]
GW876008	DMAXRBI	Discontinued in Phase 2	Small molecular drug	[35]
SLV-323	DMHRYX6	Discontinued in Phase 1	NA	[36]
SR-58878	DMS9EJ5	Terminated	NA	[37]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

This Disease is Treated as An Indication in 2 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ATI-17000	DMZJVR5	Preclinical	Small molecular drug	[7]
SLV-332	DMY9DA3	Preclinical	Small molecular drug	[7]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 6 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ALB-137391(a)	DMYKI8T	Investigative	NA	[38]
ATB-284	DMA7N9G	Investigative	NA	[38]
LPG-1030S	DM8AHQE	Investigative	NA	[38]
MLR-1045	DMYEO1V	Investigative	NA	[38]
R-1	DMK0YP7	Investigative	Small molecular drug	[39]
RQ-00310941	DMYK6OU	Investigative	NA	[39]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 69 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
CNR1	TT6OEDT	Limited	Biomarker	[40]
COMT	TTKWFB8	Limited	Genetic Variation	[41]
F2RL1	TTQR74A	Limited	Biomarker	[42]
GLP1R	TTVIMDE	Limited	Biomarker	[43]
GUCY2C	TTLDPRG	Limited	Biomarker	[44]
IL23R	TT6H4QR	Limited	Genetic Variation	[45]
PYY	TTVFJLX	Limited	Biomarker	[46]
SCN5A	TTZOVE0	Limited	Genetic Variation	[47]
TRPV1	TTMI6F5	Disputed	Biomarker	[48]
CRHR1	TT7EFHR	moderate	Biomarker	[49]
ADCY1	TTV1ZSQ	Strong	Biomarker	[50]
ADORA2B	TTNE7KG	Strong	Altered Expression	[51]
ADRA2A	TTWG9A4	Strong	Genetic Variation	[52]
ANK1	TTKFPMH	Strong	Biomarker	[53]
CCR9	TTIPS8B	Strong	Altered Expression	[54]
CFP	TTLA0VS	Strong	Genetic Variation	[55]
CHRNA5	TTH2QRX	Strong	Biomarker	[56]
CNR2	TTMSFAW	Strong	Biomarker	[57]
CRHR2	TTIY658	Strong	Altered Expression	[58]
CSF2RA	TT6MP2Z	Strong	Biomarker	[59]
FAP	TTGPQ0F	Strong	Biomarker	[60]
FDXR	TT3W4IX	Strong	Genetic Variation	[61]
FGF19	TTGCH11	Strong	Biomarker	[62]
FGFR4	TT1KX2S	Strong	Biomarker	[63]
GCG	TT6Y4PN	Strong	Biomarker	[43]
GFRA3	TT63XRS	Strong	Biomarker	[64]
GHSR	TTWDC17	Strong	Genetic Variation	[65]
GNRH1	TT0ID4A	Strong	Biomarker	[66]
GPBAR1	TTSDVTR	Strong	Biomarker	[67]
GRIA1	TTVPQTF	Strong	Biomarker	[68]
GRM7	TT0I76D	Strong	Biomarker	[69]
HTR1B	TTK8CXU	Strong	Biomarker	[70]
HTR2A	TTJQOD7	Strong	Genetic Variation	[71]
HTR2B	TT0K1SC	Strong	Biomarker	[72]
HTR3A	TTPC4TU	Strong	Biomarker	[73]
HTR4	TT07C3Y	Strong	Biomarker	[74]
HTR7	TTO9X1H	Strong	Biomarker	[75]
IL10	TTT0Q1F	Strong	Genetic Variation	[76]
KCNQ4	TT8HGRW	Strong	Altered Expression	[77]
KCNQ5	TTWVL5Q	Strong	Genetic Variation	[77]
KLB	TTARBVH	Strong	Genetic Variation	[78]
LANCL2	TTMK3EX	Strong	Altered Expression	[79]
LCT	TTA0OSE	Strong	Genetic Variation	[80]
MAGEC2	TTKGUEB	Strong	Biomarker	[81]
MCM6	TTQGKSD	Strong	Genetic Variation	[82]
MRGPRX2	TT3YV20	Strong	Genetic Variation	[83]
MYLK2	TTHLGB2	Strong	Biomarker	[84]
NLRX1	TTKT026	Strong	Biomarker	[85]
NOD2	TTYPUHA	Strong	Biomarker	[86]
NPR3	TTWVLS6	Strong	Biomarker	[87]
OPRK1	TTQW87Y	Strong	Biomarker	[88]
PEPD	TTLZXI0	Strong	Biomarker	[89]
PLK2	TT976FS	Strong	Biomarker	[81]
PRKCD	TT7A1BO	Strong	Genetic Variation	[90]
PRSS1	TT2WR1T	Strong	Biomarker	[91]
PTPN2	TTY8PUS	Strong	Genetic Variation	[92]
RPSA	TTLUW5B	Strong	Biomarker	[93]
SCG3	TTY5R9H	Strong	Biomarker	[94]
SIRPA	TTBRJS9	Strong	Altered Expression	[95]
SLC5A7	TTRV7W3	Strong	Biomarker	[96]
SSX2IP	TTZXB07	Strong	Altered Expression	[97]
TESK1	TTWKT3Y	Strong	Posttranslational Modification	[98]
TLR5	TTCXP8J	Strong	Altered Expression	[99]
TNFRSF17	TTZ3P4W	Strong	Genetic Variation	[100]
TNFRSF25	TTDV6BQ	Strong	Altered Expression	[101]
TPH2	TT3KLDP	Strong	Genetic Variation	[41]
TPSAB1	TTM1TDX	Strong	Biomarker	[102]
TST	TT51OTS	Strong	Biomarker	[103]
XDH	TT7RJY8	Strong	Altered Expression	[104]
------------------------------------------------------------------------------------


⏷ Show the Full List of 69 DTT(s)

This Disease Is Related to 1 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC26A2	DTFSLX5	Strong	Genetic Variation	[105]
------------------------------------------------------------------------------------

This Disease Is Related to 3 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
FAAH	DEUM1EX	Limited	Biomarker	[40]
SI	DE5EO4Y	Limited	Genetic Variation	[106]
TPMT	DEFQ8VO	Limited	Genetic Variation	[107]
------------------------------------------------------------------------------------

This Disease Is Related to 67 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ACAD8	OT3JI5GB	Limited	Altered Expression	[108]
ATG16L1	OTEOYC5D	Limited	Genetic Variation	[109]
C1QL1	OTNQ0G3E	Limited	Biomarker	[110]
ITGAX	OTOGIMHE	Limited	Altered Expression	[111]
NLRP6	OTEREN4W	Limited	Biomarker	[110]
OR2AG1	OTEITRP4	Limited	Altered Expression	[112]
PRSS3	OTN3S5YB	Limited	Altered Expression	[113]
ACSBG1	OTM040MW	Strong	Biomarker	[114]
APOL2	OT303Q7B	Strong	Biomarker	[115]
AQP6	OTXS6UYY	Strong	Genetic Variation	[116]
AQP8	OT99JKME	Strong	Altered Expression	[117]
BCLAF1	OT7T8H6A	Strong	Altered Expression	[118]
CCL16	OTOOQI1F	Strong	Altered Expression	[119]
CDAN1	OTCVZRG6	Strong	Biomarker	[120]
CELA3A	OT9JAL80	Strong	Biomarker	[121]
CLCN5	OT9YXZSO	Strong	Altered Expression	[122]
CLDN1	OT27KV99	Strong	Altered Expression	[123]
CLDN2	OTRF3D6Y	Strong	Altered Expression	[124]
COPE	OTBKHBT7	Strong	Biomarker	[125]
CT83	OTQEGHAB	Strong	Genetic Variation	[80]
ENDOU	OTB7OF7Y	Strong	Altered Expression	[126]
ETFA	OTXX61VZ	Strong	Biomarker	[127]
EXOSC6	OTAC10N6	Strong	Altered Expression	[126]
FATE1	OTPYXV64	Strong	Genetic Variation	[80]
FCRL3	OTIFXFWL	Strong	Biomarker	[128]
FLVCR1	OT9XCFOC	Strong	Biomarker	[129]
GSDMB	OTWA7P10	Strong	Genetic Variation	[130]
HGD	OTTKLQOO	Strong	Biomarker	[131]
HTR3E	OTIWF1R5	Strong	Biomarker	[132]
IKBKG	OTNWJWSD	Strong	Therapeutic	[133]
IRGM	OTKD3O5Z	Strong	Biomarker	[134]
ITM2B	OTMXEPXB	Strong	Biomarker	[135]
KALRN	OT8WRCBH	Strong	Biomarker	[136]
KIR2DL5A	OT09FZE1	Strong	Biomarker	[137]
KIR2DL5B	OTSV0JL9	Strong	Biomarker	[137]
KIR2DS5	OTXLEN11	Strong	Genetic Variation	[137]
KIR3DS1	OTJWIO4T	Strong	Genetic Variation	[137]
LTO1	OTQ17ZDT	Strong	Biomarker	[138]
MAGI2	OTXDDKZS	Strong	Biomarker	[139]
MAST3	OT6VVQ84	Strong	Biomarker	[140]
MLXIPL	OTR9MLLW	Strong	Biomarker	[141]
MOS	OTNMQPFJ	Strong	Genetic Variation	[142]
MYLK3	OTC58V2Q	Strong	Biomarker	[84]
NAPSA	OT6F8IAL	Strong	Genetic Variation	[108]
NCF2	OTAUW7L2	Strong	Genetic Variation	[143]
NEUROG3	OT6DIPWC	Strong	Biomarker	[144]
NKX2-3	OTF4IL5J	Strong	Genetic Variation	[145]
NMS	OTFYS4LO	Strong	Biomarker	[146]
NUDT15	OTX8SZOT	Strong	Genetic Variation	[147]
NXPH1	OTGKX860	Strong	Genetic Variation	[105]
OXT	OT48M72Z	Strong	Genetic Variation	[148]
PACC1	OTKBS8CC	Strong	Biomarker	[149]
PDIA3	OTHPQ0Q3	Strong	ModifyingMutation	[150]
PELI1	OTMLBCLC	Strong	Genetic Variation	[151]
PIEZO2	OTQ7AT38	Strong	Biomarker	[152]
PRDM6	OTKY12D9	Strong	Genetic Variation	[151]
PROK2	OT70IFEZ	Strong	Biomarker	[153]
RAN	OT2TER5M	Strong	Biomarker	[154]
RARRES2	OT1BJE8K	Strong	Biomarker	[155]
REM1	OTUXL0HC	Strong	Biomarker	[156]
RNF183	OTWPNZF9	Strong	Altered Expression	[157]
S100A10	OTI71243	Strong	Altered Expression	[70]
STH	OTK8ULTH	Strong	Altered Expression	[108]
SUMF2	OT37I8JL	Strong	Genetic Variation	[158]
SYNM	OTOI8TRJ	Strong	Biomarker	[159]
TRAF3IP2	OTLLZERL	Strong	Genetic Variation	[160]
AGA	OTNWT1WB	Definitive	Biomarker	[127]
------------------------------------------------------------------------------------


⏷ Show the Full List of 67 DOT(s)

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2296).
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3	Chlordiazepoxide FDA Label
4	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 366).
5	Dicyclomine FDA Label
6	Homatropine Methylbromide FDA Label
7	Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
8	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5017).
9	Levomilnacipran FDA Label
10	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
11	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
12	ClinicalTrials.gov (NCT01225237) A Study to Evaluate Efficacy of Ramosetron on Diarrhea-predominant Irritable Bowel Syndrome (IBS) in Male Patients. U.S. National Institutes of Health.
13	Scopolamine FDA Label
14	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
15	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2297).
16	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2117).
17	ClinicalTrials.gov (NCT00324532) to Assess the Efficacy and Safety of the Probiotic E. Coli Strain M17 on Patients With GERD. U.S. National Institutes of Health.
18	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 244).
19	ClinicalTrials.gov (NCT01896583) A Phase 2 Pilot Study to Assess ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D). U.S. National Institutes of Health.
20	ClinicalTrials.gov (NCT03721107) A Phase II Randomized, Double Blind, Placebo-controlled, Parallel Group, Multicenter Study to Evaluate the Safety and Efficacy of Repeated Oral Doses of Blautix in Adult Subjects With Irritable Bowel Syndrome (IBS) Subtypes IBS-C and IBS-D. U.S.National Institutes of Health.
21	ClinicalTrials.gov (NCT00813098) Study of LX1031 in Subjects With Non-Constipating Irritable Bowel Syndrome. U.S. National Institutes of Health.
22	ClinicalTrials.gov (NCT01494233) A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome. U.S. National Institutes of Health.
23	ClinicalTrials.gov (NCT01887002) Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D). U.S. National Institutes of Health.
24	ClinicalTrials.gov (NCT04129619) A Double-Blind, Placebo-Controlled, Phase 2, Responsive Adaptive Randomization Study of ORP-101 in Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D). U.S.National Institutes of Health.
25	Clinical pipeline report, company report or official report of Department of Pharmacology University of Wisconsin School of Medicine.
26	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2132).
27	ClinicalTrials.gov (NCT01149200) Proof-of-Principle Study of TC-6499 in the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS). U.S. National Institutes of Health.
28	ClinicalTrials.gov (NCT00486876) A Study of 3 Doses of Dextofisopam in Females With Irritable Bowel Syndrome. U.S. National Institutes of Health.
29	Clinical pipeline report, company report or official report of Cinphloro
30	ClinicalTrials.gov (NCT01633723) Phase I Clinical Trial of DA-6886 in Healthy Male Subjects. U.S. National Institutes of Health.
31	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021456)
32	Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
33	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5751).
34	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001434)
35	Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
36	Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs. 2006 Mar;11(1):137-51.
37	Clinical pipeline report, company report or official report of Sanofi-Synthelabo.
38	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
39	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 7).
40	Association of cannabinoid type 1 receptor and fatty acid amide hydrolase genetic polymorphisms in Chinese patients with irritable bowel syndrome.J Gastroenterol Hepatol. 2014 Jun;29(6):1186-91. doi: 10.1111/jgh.12513.
41	Association of Fatigue With TPH2 Genetic Polymorphisms in Women With Irritable Bowel Syndrome.Biol Res Nurs. 2019 Jan;21(1):72-79. doi: 10.1177/1099800418806055. Epub 2018 Oct 11.
42	Protease Activated Receptor-2 Induces Immune Activation and Visceral Hypersensitivity in Post-infectious Irritable Bowel Syndrome Mice.Dig Dis Sci. 2019 Mar;64(3):729-739. doi: 10.1007/s10620-018-5367-y. Epub 2018 Nov 16.
43	The Glucagon-like peptide-1 receptor agonist, exendin-4, ameliorated gastrointestinal dysfunction in the Wistar Kyoto rat model of Irritable Bowel Syndrome.Neurogastroenterol Motil. 2020 Feb;32(2):e13738. doi: 10.1111/nmo.13738. Epub 2019 Oct 11.
44	Guanylate cyclase-C as a therapeutic target in gastrointestinal disorders.Gut. 2018 Aug;67(8):1543-1552. doi: 10.1136/gutjnl-2018-316029. Epub 2018 Mar 21.
45	Candidate single nucleotide polymorphisms of irritable bowel syndrome: a systemic review and meta-analysis.BMC Gastroenterol. 2019 Oct 15;19(1):165. doi: 10.1186/s12876-019-1084-z.
46	Possible role of peptide YY (PYY) in the pathophysiology of irritable bowel syndrome (IBS).Neuropeptides. 2020 Feb;79:101973. doi: 10.1016/j.npep.2019.101973. Epub 2019 Oct 24.
47	Irritable bowel syndrome patients have SCN5A channelopathies that lead to decreased Na(V)1.5 current and mechanosensitivity.Am J Physiol Gastrointest Liver Physiol. 2018 Apr 1;314(4):G494-G503. doi: 10.1152/ajpgi.00016.2017. Epub 2017 Nov 22.
48	Bile acids induce visceral hypersensitivity via mucosal mast cell-to-nociceptor signaling that involves the farnesoid X receptor/nerve growth factor/transient receptor potential vanilloid 1 axis.FASEB J. 2019 Feb;33(2):2435-2450. doi: 10.1096/fj.201800935RR. Epub 2018 Sep 27.
49	Brain and Gut CRF Signaling: Biological Actions and Role in the Gastrointestinal Tract.Curr Mol Pharmacol. 2018;11(1):51-71. doi: 10.2174/1874467210666170224095741.
50	Cyclic AMP-dependent positive feedback signaling pathways in the cortex contributes to visceral pain.J Neurochem. 2020 Apr;153(2):252-263. doi: 10.1111/jnc.14903. Epub 2020 Feb 9.
51	The role of mechanical forces and adenosine in the regulation of intestinal enterochromaffin cell serotonin secretion.Am J Physiol Gastrointest Liver Physiol. 2012 Feb 1;302(3):G397-405. doi: 10.1152/ajpgi.00087.2011. Epub 2011 Oct 28.
52	Association of alpha 2A adrenergic receptor gene (ADRAlpha2A) polymorphism with irritable bowel syndrome, microscopic and ulcerative colitis.Clin Chim Acta. 2010 Jan;411(1-2):59-63. doi: 10.1016/j.cca.2009.10.003. Epub 2009 Oct 13.
53	Histamine-mediated potentiation of transient receptor potential (TRP) ankyrin 1 and TRP vanilloid 4 signaling in submucosal neurons in patients with irritable bowel syndrome.Am J Physiol Gastrointest Liver Physiol. 2019 Mar 1;316(3):G338-G349. doi: 10.1152/ajpgi.00116.2018. Epub 2019 Jan 10.
54	Immunohistochemical staining with chemokine panel of non-specific colitis predicts future IBD diagnosis.Cytokine. 2020 Mar;127:154935. doi: 10.1016/j.cyto.2019.154935. Epub 2019 Nov 27.
55	Altered Brain Structure and Functional Connectivity and Its Relation to Pain Perception in Girls With Irritable Bowel Syndrome.Psychosom Med. 2019 Feb/Mar;81(2):146-154. doi: 10.1097/PSY.0000000000000655.
56	Smoking Interacts With CHRNA5, a Nicotinic Acetylcholine Receptor Subunit Gene, to Influence the Risk of IBD-Related Surgery.Inflamm Bowel Dis. 2018 Apr 23;24(5):1057-1064. doi: 10.1093/ibd/izx094.
57	Activation of cannabinoid 2 receptor relieves colonic hypermotility in a rat model of irritable bowel syndrome.Neurogastroenterol Motil. 2019 Jun;31(6):e13555. doi: 10.1111/nmo.13555. Epub 2019 Feb 21.
58	The comprehensive pathophysiological changes in a novel rat model of postinflammatory visceral hypersensitivity.FASEB J. 2019 Dec;33(12):13560-13571. doi: 10.1096/fj.201901489R. Epub 2019 Sep 28.
59	Defective leukocyte GM-CSF receptor (CD116) expression and function in inflammatory bowel disease.Gastroenterology. 2011 Jul;141(1):208-16. doi: 10.1053/j.gastro.2011.03.060. Epub 2011 Apr 7.
60	Increased Gut Permeability in First-degree Relatives of Children with Irritable Bowel Syndrome or Functional Abdominal Pain.Clin Gastroenterol Hepatol. 2020 Feb;18(2):375-384.e1. doi: 10.1016/j.cgh.2019.05.011. Epub 2019 May 14.
61	Candidate genes and sensory functions in health and irritable bowel syndrome.Am J Physiol Gastrointest Liver Physiol. 2008 Aug;295(2):G219-25. doi: 10.1152/ajpgi.90202.2008. Epub 2008 May 29.
62	Bile and fat excretion are biomarkers of clinically significant diarrhoea and constipation in irritable bowel syndrome.Aliment Pharmacol Ther. 2019 Mar;49(6):744-758. doi: 10.1111/apt.15106. Epub 2019 Feb 10.
63	Irritable bowel syndrome-diarrhea: characterization of genotype by exome sequencing, and phenotypes of bile acid synthesis and colonic transit.Am J Physiol Gastrointest Liver Physiol. 2014 Jan 1;306(1):G13-26. doi: 10.1152/ajpgi.00294.2013. Epub 2013 Nov 7.
64	Effect of moxibustion on the expression of GDNF and its receptor GFR3 in the colon and spinal cord of rats with irritable bowel syndrome.Acupunct Med. 2019 Aug;37(4):244-251. doi: 10.1136/acupmed-2017-011455. Epub 2019 Jun 12.
65	GHSR-1 agonist sensitizes rat colonic intrinsic and extrinsic neurons to exendin-4: A role in the manifestation of postprandial gastrointestinal symptoms in irritable bowel syndrome?.Neurogastroenterol Motil. 2019 Oct;31(10):e13684. doi: 10.1111/nmo.13684. Epub 2019 Jul 16.
66	Gonadotropin-Releasing Hormone and Its Role in the Enteric Nervous System.Front Endocrinol (Lausanne). 2017 Jun 7;8:110. doi: 10.3389/fendo.2017.00110. eCollection 2017.
67	Genetic variation in GPBAR1 predisposes to quantitative changes in colonic transit and bile acid excretion.Am J Physiol Gastrointest Liver Physiol. 2014 Sep 1;307(5):G508-16. doi: 10.1152/ajpgi.00178.2014. Epub 2014 Jul 10.
68	Hippocampal AMPARs involve the central sensitization of rats with irritable bowel syndrome.Brain Behav. 2017 Feb 22;7(3):e00650. doi: 10.1002/brb3.650. eCollection 2017 Mar.
69	Activating metabotropic glutamate receptor? attenuates visceral hypersensitivity in neonatal maternally separated rats.Int J Mol Med. 2019 Feb;43(2):761-770. doi: 10.3892/ijmm.2018.4022. Epub 2018 Dec 11.
70	S100A expression and interleukin-10 polymorphisms are associated with ulcerative colitis and diarrhea predominant irritable bowel syndrome.Dig Dis Sci. 2013 Aug;58(8):2314-23. doi: 10.1007/s10620-013-2677-y. Epub 2013 Apr 18.
71	5-HT2A receptor gene polymorphisms and irritable bowel syndrome.J Clin Gastroenterol. 2011 Jul;45(6):514-7. doi: 10.1097/MCG.0b013e318205e13b.
72	5-HT(2B) receptors play a key role in mediating the excitatory effects of 5-HT in human colon in vitro.Br J Pharmacol. 2002 Mar;135(5):1144-51. doi: 10.1038/sj.bjp.0704571.
73	Optimal dose of ramosetron in female patients with irritablebowel syndrome with diarrhea: A randomized, placebo-controlled phase II study.Neurogastroenterol Motil. 2017 Jun;29(6). doi: 10.1111/nmo.13023. Epub 2017 Feb 16.
74	miR-16 and miR-103 impact 5-HT(4) receptor signalling and correlate with symptom profile in irritable bowel syndrome.Sci Rep. 2017 Oct 31;7(1):14680. doi: 10.1038/s41598-017-13982-0.
75	MiRNA-29a modulates visceral hyperalgesia in irritable bowel syndrome by targeting HTR7.Biochem Biophys Res Commun. 2019 Apr 9;511(3):671-678. doi: 10.1016/j.bbrc.2019.02.126. Epub 2019 Feb 28.
76	Phenotypic characteristics and clinical manifestations of inflammatory bowel disease in infants and children under 2 years of age in Liaoning Province, China: five of six infants with IL-10R mutations.Paediatr Int Child Health. 2019 Feb;39(1):59-64. doi: 10.1080/20469047.2018.1560700.
77	Application of a combination of a knowledge-based algorithm and 2-stage screening to hypothesis-free genomic data on irinotecan-treated patients for identification of a candidate single nucleotide polymorphism related to an adverse effect.PLoS One. 2014 Aug 15;9(8):e105160. doi: 10.1371/journal.pone.0105160. eCollection 2014.
78	Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome.Am J Physiol Gastrointest Liver Physiol. 2012 May 15;302(10):G1075-84. doi: 10.1152/ajpgi.00537.2011. Epub 2012 Mar 8.
79	Activation of LANCL2 by BT-11 Ameliorates IBD by Supporting Regulatory T Cell Stability Through Immunometabolic Mechanisms.Inflamm Bowel Dis. 2018 Aug 16;24(9):1978-1991. doi: 10.1093/ibd/izy167.
80	Lactase persistence/non-persistence genetic variants in irritable bowel syndrome in an endemic area for lactose malabsorption.J Gastroenterol Hepatol. 2012 Dec;27(12):1825-30. doi: 10.1111/j.1440-1746.2012.07259.x.
81	Up-regulation of microRNA-126 may contribute to pathogenesis of ulcerative colitis via regulating NF-kappaB inhibitor IB.PLoS One. 2012;7(12):e52782. doi: 10.1371/journal.pone.0052782. Epub 2012 Dec 28.
82	Comparison of Lactase Variant MCM6 -13910 C>T Testing and Self-report of Dairy Sensitivity in Patients With Irritable Bowel Syndrome.J Clin Gastroenterol. 2019 Jul;53(6):e227-e231. doi: 10.1097/MCG.0000000000001065.
83	Expression of immune-related genes in rectum and colon descendens of Irritable Bowel Syndrome patients is unrelated to clinical symptoms.Neurogastroenterol Motil. 2019 Jun;31(6):e13579. doi: 10.1111/nmo.13579. Epub 2019 Mar 10.
84	MLCK-mediated intestinal permeability promotes immune activation and visceral hypersensitivity in PI-IBS mice.Neurogastroenterol Motil. 2018 Sep;30(9):e13348. doi: 10.1111/nmo.13348. Epub 2018 Apr 11.
85	Exploratory studies with NX-13: oral toxicity and pharmacokinetics in rodents of an orally active, gut-restricted first-in-class therapeutic for IBD that targets NLRX1. Drug Chem Toxicol. 2022 Jan;45(1):209-214.
86	Ankylosing Spondylitis and Axial Spondyloarthritis in Patients With Long-term Inflammatory Bowel Disease: Results From 20 Years of Follow-up in the IBSEN Study.J Crohns Colitis. 2018 Jan 5;12(1):96-104. doi: 10.1093/ecco-jcc/jjx126.
87	Plecanatide for Treatment of Chronic Constipation and Irritable Bowel Syndrome.Am J Med. 2019 May;132(5):572-575. doi: 10.1016/j.amjmed.2018.11.027. Epub 2018 Dec 11.
88	High throughput -SPE based elution coupled with UPLC-MS/MS for determination of eluxadoline in plasma sample: Application in pharmacokinetic characterization of PLGA nanoparticle formulations in rats.J Pharm Biomed Anal. 2018 Feb 5;149:172-178. doi: 10.1016/j.jpba.2017.10.024. Epub 2017 Oct 28.
89	Elevated fecal peptidase D at onset of colitis in Galphai2-/- mice, a mouse model of IBD.PLoS One. 2017 Mar 21;12(3):e0174275. doi: 10.1371/journal.pone.0174275. eCollection 2017.
90	Cognitive behavioural therapy for irritable bowel syndrome: 24-month follow-up of participants in the ACTIB randomised trial.Lancet Gastroenterol Hepatol. 2019 Nov;4(11):863-872. doi: 10.1016/S2468-1253(19)30243-2. Epub 2019 Sep 3.
91	Exploring the multicomponent synergy mechanism of Banxia Xiexin Decoction on irritable bowel syndrome by a systems pharmacology strategy.J Ethnopharmacol. 2019 Apr 6;233:158-168. doi: 10.1016/j.jep.2018.12.033. Epub 2018 Dec 24.
92	The presence of genetic risk variants within PTPN2 and PTPN22 is associated with intestinal microbiota alterations in Swiss IBD cohort patients.PLoS One. 2018 Jul 2;13(7):e0199664. doi: 10.1371/journal.pone.0199664. eCollection 2018.
93	Proteomic analysis of colonic mucosa in a rat model of irritable bowel syndrome.Proteomics. 2010 Jul;10(14):2620-30. doi: 10.1002/pmic.200900572.
94	Evidence of increased fecal granins in children with irritable bowel syndrome and correlates with symptoms.Neurogastroenterol Motil. 2019 Jan;31(1):e13486. doi: 10.1111/nmo.13486. Epub 2018 Oct 9.
95	Clostridium butyricum regulates visceral hypersensitivity of irritable bowel syndrome by inhibiting colonic mucous low grade inflammation through its action on NLRP6.Acta Biochim Biophys Sin (Shanghai). 2018 Feb 1;50(2):216-223. doi: 10.1093/abbs/gmx138.
96	Role of High-affinity Choline Transporter 1 in Colonic Hypermotility in a Rat Model of Irritable Bowel Syndrome.J Neurogastroenterol Motil. 2018 Oct 1;24(4):643-655. doi: 10.5056/jnm18040.
97	Transcriptome and methylome profiling in a rat model of irritable bowel syndrome induced by stress.Int J Mol Med. 2018 Nov;42(5):2641-2649. doi: 10.3892/ijmm.2018.3823. Epub 2018 Aug 14.
98	Decreased TESK1-mediated cofilin 1 phosphorylation in the jejunum of IBS-D patients may explain increased female predisposition to epithelial dysfunction.Sci Rep. 2018 Feb 2;8(1):2255. doi: 10.1038/s41598-018-20540-9.
99	Expression of Toll-like Receptors, Pro-, and Anti-inflammatory Cytokines in Relation to Gut Microbiota in Irritable Bowel Syndrome: The Evidence for Its Micro-organic Basis.J Neurogastroenterol Motil. 2018 Oct 1;24(4):628-642. doi: 10.5056/jnm18130.
100	Identification of single nucleotide polymorphisms in the TNFRSF17 gene and their association with gastrointestinal disorders.Mol Cells. 2010 Jan;29(1):21-8. doi: 10.1007/s10059-010-0002-6. Epub 2009 Dec 7.
101	Expression of death receptor 3 on peripheral blood mononuclear cells differes in adult IBD patients and children with newly diagnosed IBD.Cytometry B Clin Cytom. 2017 Mar;92(2):165-169. doi: 10.1002/cyto.b.21372. Epub 2016 May 6.
102	Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number.Nat Genet. 2016 Dec;48(12):1564-1569. doi: 10.1038/ng.3696. Epub 2016 Oct 17.
103	Serial Tuberculin Skin Tests Improve the Detection of Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease.J Crohns Colitis. 2018 Nov 15;12(11):1270-1279. doi: 10.1093/ecco-jcc/jjy104.
104	High inter-individual variability of serum xanthine oxidoreductase activity in IBD patients.Nucleosides Nucleotides Nucleic Acids. 2018;37(6):317-323. doi: 10.1080/15257770.2018.1460477. Epub 2018 May 3.
105	Genetic variants in CDC42 and NXPH1 as susceptibility factors for constipation and diarrhoea predominant irritable bowel syndrome.Gut. 2014 Jul;63(7):1103-11. doi: 10.1136/gutjnl-2013-304570. Epub 2013 Sep 16.
106	Heterozygotes Are a Potential New Entity among Homozygotes and Compound Heterozygotes in Congenital Sucrase-Isomaltase Deficiency.Nutrients. 2019 Sep 25;11(10):2290. doi: 10.3390/nu11102290.
107	Thiopurine Methyltransferase Genetic Polymorphisms and Activity and Metabolic Products of Azathioprine in Patients with Inflammatory Bowel Disease.Endocr Metab Immune Disord Drug Targets. 2019;19(4):541-547. doi: 10.2174/1871530318666181119153522.
108	21st century research in urban WASH and health in sub-Saharan Africa: methods and outcomes in transition.Int J Environ Health Res. 2019 Aug;29(4):457-478. doi: 10.1080/09603123.2018.1550193. Epub 2018 Dec 13.
109	Protein tyrosine phosphatase nonreceptor type 2 regulates autophagosome formation in human intestinal cells.Inflamm Bowel Dis. 2012 Jul;18(7):1287-302. doi: 10.1002/ibd.21891. Epub 2011 Oct 10.
110	Corticotropin-releasing factor induces inflammatory cytokines via the NLRP6-inflammatory cytokine axis in a murine model of irritable bowel syndrome.J Dig Dis. 2019 Mar;20(3):143-151. doi: 10.1111/1751-2980.12704. Epub 2019 Mar 5.
111	Clostridium butyricum alleviates intestinal low-grade inflammation in TNBS-induced irritable bowel syndrome in mice by regulating functional status of lamina propria dendritic cells.World J Gastroenterol. 2019 Sep 28;25(36):5469-5482. doi: 10.3748/wjg.v25.i36.5469.
112	Agomelatine, a novel therapeutic option for the management of irritable bowel syndrome.J Clin Pharm Ther. 2018 Oct;43(5):752-756. doi: 10.1111/jcpt.12749. Epub 2018 Jul 16.
113	Epithelial expression and function of trypsin-3 in irritable bowel syndrome.Gut. 2017 Oct;66(10):1767-1778. doi: 10.1136/gutjnl-2016-312094. Epub 2017 Jan 17.
114	Ulcerative colitis, Crohn's disease, and irritable bowel syndrome have different profiles of extracellular matrix turnover, which also reflects disease activity in Crohn's disease.PLoS One. 2017 Oct 13;12(10):e0185855. doi: 10.1371/journal.pone.0185855. eCollection 2017.
115	Gene expression profiles in peripheral blood mononuclear cells correlate with salience network activity in chronic visceral pain: A pilot study.Neurogastroenterol Motil. 2017 Jun;29(6):10.1111/nmo.13027. doi: 10.1111/nmo.13027. Epub 2017 Feb 12.
116	Response pattern analysis of IBD-KID: A knowledge assessment tool for children with inflammatory bowel disease.J Paediatr Child Health. 2020 Jan;56(1):155-162. doi: 10.1111/jpc.14547. Epub 2019 Jun 26.
117	Aquaporins 1, 3 and 8 expression in irritable bowel syndrome rats' colon via NF-B pathway.Oncotarget. 2017 Jul 18;8(29):47175-47183. doi: 10.18632/oncotarget.17565.
118	Interactome based biomarker discovery for irritable bowel syndrome-A systems biology approach.Comput Biol Chem. 2018 Oct;76:218-224. doi: 10.1016/j.compbiolchem.2018.07.007. Epub 2018 Jul 10.
119	Pro-inflammatory chemokine C-C motif ligand 16 (CCL-16) dysregulation in irritable bowel syndrome (IBS): a pilot study.Neurogastroenterol Motil. 2011 Dec;23(12):1092-7. doi: 10.1111/j.1365-2982.2011.01792.x. Epub 2011 Sep 23.
120	The appearance of joint manifestations in the Swiss inflammatory bowel disease cohort.PLoS One. 2019 Apr 30;14(4):e0211554. doi: 10.1371/journal.pone.0211554. eCollection 2019.
121	Protease signaling through protease activated receptor 1 mediate nerve activation by mucosal supernatants from irritable bowel syndrome but not from ulcerative colitis patients.PLoS One. 2018 Mar 12;13(3):e0193943. doi: 10.1371/journal.pone.0193943. eCollection 2018.
122	Downregulation of sodium transporters and NHERF proteins in IBD patients and mouse colitis models: potential contributors to IBD-associated diarrhea.Inflamm Bowel Dis. 2009 Feb;15(2):261-74. doi: 10.1002/ibd.20743.
123	Upregulated claudin-1 expression promotes colitis-associated cancer by promoting -catenin phosphorylation and activation in Notch/p-AKT-dependent manner.Oncogene. 2019 Jun;38(26):5321-5337. doi: 10.1038/s41388-019-0795-5. Epub 2019 Apr 10.
124	miR-16 and miR-125b are involved in barrier function dysregulation through the modulation of claudin-2 and cingulin expression in the jejunum in IBS with diarrhoea.Gut. 2017 Sep;66(9):1537-1538. doi: 10.1136/gutjnl-2016-311477. Epub 2017 Jan 12.
125	Relations between symptom severity, illness perceptions, visceral sensitivity, coping strategies and well-being in irritable bowel syndrome guided by the common sense model of illness.Psychol Health Med. 2017 Jun;22(5):524-534. doi: 10.1080/13548506.2016.1168932. Epub 2016 Apr 4.
126	Alterations in expression of p11 and SERT in mucosal biopsy specimens of patients with irritable bowel syndrome.Gastroenterology. 2007 Jan;132(1):17-25. doi: 10.1053/j.gastro.2006.11.020. Epub 2006 Nov 17.
127	Coeliac disease.Paediatr Int Child Health. 2019 Feb;39(1):23-31. doi: 10.1080/20469047.2018.1504431. Epub 2018 Aug 13.
128	Epistatic interaction between FCRL3 and MHC in Spanish patients with IBD.Tissue Antigens. 2007 Apr;69(4):313-7. doi: 10.1111/j.1399-0039.2007.00816.x.
129	Anxiety and depression in irritable bowel syndrome: Exploring the interaction with other symptoms and pathophysiology using multivariate analyses.Neurogastroenterol Motil. 2019 Aug;31(8):e13619. doi: 10.1111/nmo.13619. Epub 2019 May 5.
130	Gene polymorphism linked to increased asthma and IBD risk alters gasdermin-B structure, a sulfatide and phosphoinositide binding protein.Proc Natl Acad Sci U S A. 2017 Feb 14;114(7):E1128-E1137. doi: 10.1073/pnas.1616783114. Epub 2017 Feb 1.
131	Long-term Risk of Advanced Neoplasia After Colonic Low-grade Dysplasia in Patients With Inflammatory Bowel Disease: A Nationwide Cohort Study.J Crohns Colitis. 2019 Dec 10;13(12):1485-1491. doi: 10.1093/ecco-jcc/jjz114.
132	First evidence for an association of a functional variant in the microRNA-510 target site of the serotonin receptor-type 3E gene with diarrhea predominant irritable bowel syndrome.Hum Mol Genet. 2008 Oct 1;17(19):2967-77. doi: 10.1093/hmg/ddn195. Epub 2008 Jul 9.
133	Colon-targeted cell-permeable NFB inhibitory peptide is orally active against experimental colitis.Mol Pharm. 2012 May 7;9(5):1310-9. doi: 10.1021/mp200591q. Epub 2012 Mar 27.
134	Autophagy-related IRGM genes confer susceptibility to ankylosing spondylitis in a Chinese female population: a case-control study.Genes Immun. 2017 Jan;18(1):42-47. doi: 10.1038/gene.2016.48. Epub 2016 Dec 29.
135	What impact do Rome IV criteria have on patients with IBS in China?.Scand J Gastroenterol. 2019 Dec;54(12):1433-1440. doi: 10.1080/00365521.2019.1698650. Epub 2019 Dec 12.
136	Efficacy of different probiotic protocols in irritable bowel syndrome: A network meta-analysis.Medicine (Baltimore). 2019 Jul;98(27):e16068. doi: 10.1097/MD.0000000000016068.
137	Killer immunoglobulin-like receptor repertoire analysis in a Caucasian Spanish cohort with inflammatory bowel disease.Microbiol Immunol. 2016 Nov;60(11):787-792. doi: 10.1111/1348-0421.12447.
138	VP2 of Infectious Bursal Disease Virus Induces Apoptosis via Triggering Oral Cancer Overexpressed 1 (ORAOV1) Protein Degradation.Front Microbiol. 2017 Jul 19;8:1351. doi: 10.3389/fmicb.2017.01351. eCollection 2017.
139	Intestinal epithelial barrier dysfunction in disease and possible therapeutical interventions.Curr Med Chem. 2011;18(3):398-426. doi: 10.2174/092986711794839179.
140	MAST3: a novel IBD risk factor that modulates TLR4 signaling.Genes Immun. 2008 Oct;9(7):602-12. doi: 10.1038/gene.2008.57. Epub 2008 Jul 24.
141	Recent insights into the role of ChREBP in intestinal fructose absorption and metabolism.BMB Rep. 2018 Sep;51(9):429-436. doi: 10.5483/BMBRep.2018.51.9.197.
142	Transcutaneous electric nerve stimulation over acupoints for patients with diarrhea-predominant irritable bowel syndrome: Protocol for systematic review and meta-analysis.Medicine (Baltimore). 2018 Dec;97(51):e13267. doi: 10.1097/MD.0000000000013267.
143	NADPH oxidase complex and IBD candidate gene studies: identification of a rare variant in NCF2 that results in reduced binding to RAC2.Gut. 2012 Jul;61(7):1028-35. doi: 10.1136/gutjnl-2011-300078. Epub 2011 Sep 7.
144	Enteroendocrine, Musashi 1 and neurogenin 3 cells in the large intestine of Thai and Norwegian patients with irritable bowel syndrome.Scand J Gastroenterol. 2017 Dec;52(12):1331-1339. doi: 10.1080/00365521.2017.1371793. Epub 2017 Aug 30.
145	NKX2-3 variant rs11190140 is associated with IBD and alters binding of NFAT.Mol Genet Metab. 2011 Sep-Oct;104(1-2):174-9. doi: 10.1016/j.ymgme.2011.06.023. Epub 2011 Jul 6.
146	From psychology to physicality: how nerve growth factor transduces early life stress into gastrointestinal motility disorders later in life.Cell Cycle. 2019 Aug;18(16):1824-1829. doi: 10.1080/15384101.2019.1637203. Epub 2019 Jul 4.
147	NUDT15 R139C causes thiopurine-induced early severe hair loss and leukopenia in Japanese patients with IBD.Pharmacogenomics J. 2016 Jun;16(3):280-5. doi: 10.1038/tpj.2015.43. Epub 2015 Jun 16.
148	Polymorphism in the oxytocin promoter region in patients with lactase non-persistence is not related to symptoms.BMC Gastroenterol. 2009 Nov 30;9:90. doi: 10.1186/1471-230X-9-90.
149	Breath Methane Does Not Correlate With Constipation Severity or Bloating in Patients With Constipation.J Clin Gastroenterol. 2020 Apr;54(4):365-369. doi: 10.1097/MCG.0000000000001239.
150	The effect of PDIA3 gene knockout on the mucosal immune function in IBS rats.Int J Clin Exp Med. 2015 May 15;8(5):6866-77. eCollection 2015.
151	A Measure of Suffering in relation to Anxiety and Quality of Life in IBS Patients: Preliminary Results.Biomed Res Int. 2017;2017:2387681. doi: 10.1155/2017/2387681. Epub 2017 Jul 4.
152	Piezo2: A Candidate Biomarker for Visceral Hypersensitivity in Irritable Bowel Syndrome?.J Neurogastroenterol Motil. 2017 Jul 30;23(3):453-463. doi: 10.5056/jnm16114.
153	Increased prokineticin 2 expression in gut inflammation: role in visceral pain and intestinal ion transport.Neurogastroenterol Motil. 2012 Jan;24(1):65-75, e12. doi: 10.1111/j.1365-2982.2011.01804.x. Epub 2011 Nov 3.
154	Gastrointestinal Adverse Events of Cannabinoid 1 Receptor Inverse Agonists suggest their Potential Use in Irritable Bowel Syndrome with Constipation: A Systematic Review and Meta-Analysis.J Gastrointestin Liver Dis. 2019 Dec 9;28(4):473-481. doi: 10.15403/jgld-265.
155	Serum Levels of Chemerin, Apelin, and Adiponectin in Relation to Clinical Symptoms, Quality of Life, and Psychological Factors in Irritable Bowel Syndrome.J Clin Gastroenterol. 2020 May/Jun;54(5):e40-e49. doi: 10.1097/MCG.0000000000001227.
156	Pharmacological treatments for functional nausea and functional dyspepsia in children: a systematic review.Expert Rev Clin Pharmacol. 2018 Dec;11(12):1195-1208. doi: 10.1080/17512433.2018.1540298. Epub 2018 Dec 6.
157	E3 Ubiquitin ligase RNF183 Is a Novel Regulator in Inflammatory Bowel Disease.J Crohns Colitis. 2016 Jun;10(6):713-25. doi: 10.1093/ecco-jcc/jjw023. Epub 2016 Jan 27.
158	Carriage of Clostridium difficile in outpatients with irritable bowel syndrome.J Med Microbiol. 2012 Sep;61(Pt 9):1290-1294. doi: 10.1099/jmm.0.040568-0. Epub 2012 May 11.
159	Gut Microbiota-Based Therapies for Irritable Bowel Syndrome.Clin Transl Gastroenterol. 2018 Feb 15;9(2):e134. doi: 10.1038/ctg.2018.2.
160	TRAF3IP2 gene is associated with cutaneous extraintestinal manifestations in inflammatory bowel disease.J Crohns Colitis. 2013 Feb;7(1):44-52. doi: 10.1016/j.crohns.2012.02.020. Epub 2012 Mar 24.